Screener
PTC Therapeutics PTCT Q2 2026 earnings
Reported July 30, 2026 · After market close
Revenue$360.5MBeat by $61.9M
EPS$0.92Beat by $0.68
Revenue estimate$298.6M
EPS estimate$0.24
“We also made a number of advances in our R&D pipeline, including identification of our next small molecule splicing development candidate, PTC303, targeting somatic expansion disorders including Huntington's disease and myotonic dystrophy. In addition, we initiated the Phase 1 study of PTC612, our differentiated NLRP3 small molecule.”
Next report
Nov 3, 2026 (in 2 months)Revenue estimate$303.9M
EPS estimate$0.29
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did PTC Therapeutics report Q2 2026 earnings?
- PTC Therapeutics (PTCT) reported Q2 2026 earnings on July 30, 2026 after market close.
- What were PTC Therapeutics's Q2 2026 revenue and EPS?
- PTC Therapeutics reported revenue of $360.5M and eps of $0.92 for Q2 2026.
- Did PTC Therapeutics beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $298.6M by $61.9M. EPS beat the consensus estimate of $0.24 by $0.68.
- How did PTC Therapeutics's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 101.5% from $178.9M a year earlier.
- Where can I find PTC Therapeutics's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001070081-26-000016) and the 10-Q periodic report (0001070081-26-000017) directly on SEC EDGAR. The filing index links above go to sec.gov.
